loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

J B Chemicals & Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
J B Chemicals & Pharmaceuticals Ltd. 15 May 2025 11:26 AM
Result PDF

Q4FY25 & FY25 Result Announced for J B Chemicals & Pharmaceuticals Ltd.

Pharmaceuticals company J B Chemicals & Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • JB Pharma recorded revenue growth of 10% to Rs 949 crore
  • Operating EBITDA registered YoY growth of 15% to Rs 240 crore; Operating EBITDA margins were at 25.3% (YoY improvement of 90 bps)
  • Gross Profit improved by 12% to Rs 628 crore
    • Despite the in-licensed opthal business which has limited margins, Gross Profit margins witnessed YoY improvement of 90 bps, reaching 66.1%
  • Due to tight control on overheads, other expenses as percentage to sales reduced by 80 bps to 23.7%
  • Depreciation increased to Rs 46 crore as compared to Rs 41 crore
  • Finance cost reduced to Rs 1 crore vs Rs 9 crore on account of debt repayment during the year
  • Other income was at Rs 14 crore vs Rs 17 crore
  • PAT increased to Rs 146 crore in Q4FY25, recording YoY growth of 15%

FY25 Financial Highlights:

  • Total revenue for the organization grew 12% to Rs 3,918 crore
  • Operating EBITDA surpassed Rs 1,000 crore for the first time to Rs 1,087 crore (YoY growth of 16%); Operating EBITDA margins improved by 70 bps to 27.7%
  • Gross Margin witnessed improvement of 30 bps to 66.4% as compared to 66.1 %
  • Non-cash ESOP costs was at Rs 55 crore v/s Rs 42 crore
  • Other Expenses as a percentage to sales witnessed YoY improvement of 60 bps to 22.5% in FY25
  • Depreciation increased to Rs 171 crore from Rs 138 crore on account of amortization of acquired/inlicensed brands
  • Effective tax rate for the year was 25.9% as compared to 26.5%
  • Net Profit increased by 19% to Rs 660 crore

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “We have closed the financial year FY25 on a strong note, in line with our strategic intent and sustained execution in the market. Our Domestic business continues to be one of the fastest growing in IPM. We have built a strong foundation over the last five years. With 75% of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward.

The CDMO business which is another focus area bounced back strongly in second half of the year. Together our Domestic and CDMO business now constitute 69% of overall revenues - Both businesses enjoy high ROCEs & high operating margins and contributed strongly towards enhancing profitability of the organisation.

Our outlook on growth is based on expansion within Domestic and CDMO businesses, as we have outlined consistently. A number of factors drive this growth include building on our existing brand franchises within India & executing key marquee projects in CDMO. We are confident therefore of charting superior growth and delivering improved profitability in the medium to longer term.

Result PDF

Result PDF

Pharmaceuticals company J B Chemicals & Pharmaceuticals announced Q3FY25 results

Financial Highlights:

  • JB Pharma recorded revenue of Rs 963 crore in the third quarter of FY25 registering growth of 14% from Rs 845 crore in Q3FY24.
  • Operating EBITDA (Earnings before Interest Depreciation and Taxes) improved by 15% to Rs 270 crore.
  • Profit after Taxes registered strong growth of 22% to Rs 162 crore vs Rs 134 crore in Q3FY24.

Other Highlights:

  • JB Pharma registered revenue of Rs 963 crore in Q3FY25 (YoY growth of 14%) and Rs 2969 crore in 9MFY25 (YoY growth of 13%).
  • Domestic formulations business recorded revenue of Rs 566 crore vs Rs 462 crore (YoY growth of 22%).
    • JB Pharma continues to remain one of the fastest growing companies in the industry.
  • International business revenue grew by 4% at Rs 397 crore vs Rs 383 crore.
    • CDMO business showed improved traction recording growth of 33% for Q3FY25.
  • Domestic and CDMO business revenue combined constitutes 70% of overall revenue for 9MFY25.
  • Operating EBITDA was Rs 270 crore in Q3FY25 (YoY growth of 15%) and Rs 846 crore in 9MFY25 (YoY growth of 16%).
    • Operating EBITDA margin improved to 28.1% for Q3FY25 YoY and improved to 28.5% for 9MFY25 YoY.
  • Gross margins were at 67.1% for Q3FY25 and 66.5% for 9MFY25.
    • Excluding ophthalmology business, gross margins improved for Q3FY25 and 9MFY25.
    • Cost optimization efforts, favorable product mix and price growth positively impacted gross margin.
  • Other expenditure as percentage to sales improved to 22.7% in Q3FY25 v/s 23.2% in Q3FY24.
  • Depreciation expenses remained the same as Q2FY25 at Rs 42 crore.
  • Finance cost reduced to Rs 3 crore vs Rs 12 crore due to decrease in gross debt.
    • Gross debt was Rs 54 crore and Net Cash was Rs 516 crore as on Dec 31, 2024.
  • Net Profit improved by 22% YoY to Rs 162 crore vs Rs 134 crore.

Nikhil Chopra, CEO and Wholetime Director, JB Pharma, said: “JB has delivered consistent growth over last few years even amidst a volatile macroeconomic environment. This has been enabled by our mix of businesses and markets, specifically our focus on India branded formulations, CDMO, and select international markets which play to our strengths, with limited revenues in countries that might present trade-related or economic volatility challenges.

JB is well-positioned to deliver continued growth going forward as well. The strategy and levers are well-defined, and we have a strong team that will execute. Our India business continues to drive market beating growth led by chronic business and progressive portfolio within the acute segment. Our export business continues to be steady with sequential improvement witnessed in our CDMO business. While the growth run-rate of JB’s quarterly performance has been maintained, we have also improved our operating margins driven by product mix and efficiency initiatives.

Advancement of various new projects in the CDMO business will flow through into growth numbers in the near to medium term, and we have a good pipeline of future product commercialization opportunities in international business which will deliver continued growth.”

Result PDF

J B Chemicals & Pharmaceuticals announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • JB Pharma recorded revenue growth of 13% to Rs 862 crore
  • Domestic business revenue grew 22% to Rs 465 crore
    • Excluding recently added ophthalmology portfolio, organic growth for domestic business was 13%
  • International business revenue grew 4% to Rs 397 crore
    • Excluding South Africa business, International formulations business registered YoY growth of 15%
    • For the first time ever in any fourth quarter, CDMO business crossed Rs 100 crore revenue
  • Operating EBITDA registered YoY growth of 16% to Rs 210 crore; Operating EBITDA margins were at 24.4% (YoY improvement of 60 bps)
  • Gross Profit improved by 15% to Rs 561 crore
    • Gross Profit margins witnessed YoY improvement of 130 bps, reaching 65.2%
  • Other Expenses increased to Rs 211 crore vs Rs 188 crore primarily due to high freight costs on account of the international business
  • Depreciation increased to Rs 41 crore as compared to Rs 32 crore primarily on account of amortization of the ophthalmology distribution and promotion license fees
  • Finance cost reduced to Rs 9 crore vs Rs 14 crore on account of debt repayment during the quarter
  • Other income surged to Rs 17 crore vs Rs 5 crore in Q4FY23 primarily due to fair value income of certain investments
  • PAT improved to Rs 126 crore in Q4FY24, recording YoY growth of 43%

FY24 Financial Highlights:

  • Total revenue for the organization grew 11% to Rs 3,484 crore
    • Excluding South Africa business and recently added ophthalmology portfolio, revenue registered YoY growth of 13%
  • Domestic business revenue registered growth of 16% to Rs 1,897 crore
    • Excluding ophthalmology portfolio, domestic business grew 13%
    • Acute season remained weak throughout the year and impacted overall growth
  •  International business grew 5% to Rs 1,587 crore
    • Overall revenue growth impacted by strategic choices made in international business especially South Africa
    • Excluding South Africa business, International business revenue registered YoY growth of 12%
  • Operating EBITDA was Rs 939 crore vs Rs 765 crore (YoY growth of 23%); Operating margins improved by 270 bps to 27%
  • Gross Margin witnessed improvement of 320 bps to 66.1% as compared to 62.9 %
    • Gross Profit reported was Rs 2,302 crore vs Rs 1,981 crore, an increase of 16%
    • Cost optimization efforts and a favorable product mix were the primary factors which enhanced margins
  • Non-cash ESOP costs reduced to Rs 42 crore from Rs 69 crore
    • ESOP costs as a percentage to Reported EBITDA reduced to 6% from 10%
  • Other Expenses as a percentage to sales witnessed YoY improvement of 50 bps to 23.1% in FY24. This is despite freight costs escalating due to ongoing geopolitical issues
  • Depreciation increased to Rs 138 crore from Rs 114 crore on account of amortization of acquired brands
  • Other Income increased to Rs 37 crore as compared to Rs 10 crore on account of increased investments and fair value income of certain investments
  • Effective tax rate for the year was 26.4% as compared to 26.1%
  • Net Profit increased 35% to Rs 553 crore
  • Operating cash flows in FY24 was Rs 801 crore vs Rs 626 crore in FY23
    • Operating cash flows to operating EBITDA improved to 85% in FY24 vs 82% in FY23
  • ROCE improved to 27% vs 21% in FY23 on the back of strong growth in profitability
  • Gross Debt reduced to Rs 357 crore as on 31st Mar 2024 from Rs 548 crore as on 31st Mar 2023
    • Cash and Cash equivalents (including investments in mutual funds) were at Rs 464 crore as on 31st Mar 2024 up from Rs 282 crore as on 31st Mar 2023
    • JB Pharma now a cash positive company with a net cash position of Rs 107 crore as on 31st Mar 2024
  • Net Working Capital was 87 days in FY24 vs 89 days in FY23
  • Net Capex additions for the year was Rs 135 crore chiefly on account of expansion of the lozenges manufacturing facility in Daman

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “JB Pharma continued its momentum in the quarter with market beating growth in domestic business. With strong focus on our leading brands, we continue to drive higher than market volume growth and gain share in our core therapeutic areas. The Ophthalmology portfolio has seen smooth transition in Jan’24 and the business has started to gain momentum.

The International business excluding South Africa recorded double-digit growth. The focus on improving business mix and cost management strategies has helped international business improve overall operating margins despite increase in freight costs on account of geo-political issues.

With continued thrust on Domestic and CDMO businesses, we feel confident that the company will continue to deliver sustained revenue growth and improved operating margins in the medium to long term.”

Result PDF

J B Chemicals & Pharmaceuticals announced Q3FY24 & 9MFY24 results:

  • JB Pharma registered revenue of Rs 845 crore in Q3FY24 (YoY growth of 7%) and Rs 2,622 crore in 9MFY24 (YoY growth of 10%)
    • Overall revenue growth impacted by strategic choices made in international business especially South Africa
    • Excluding South Africa business, revenue grew by 10% in Q3FY24 and 14% in 9MFY24
  • Domestic formulations business continued its momentum recording growth of 14% in Q3FY24 as well as in 9MFY24
    • Our chronic portfolio continues to outpace market growth led by key brands
  • In Q3FY24, International business revenue declined by 1% to Rs 383 crore due to the South Africa business
    • In 9MFY24, International business revenue was at Rs 1,190 crore (YoY growth of 6%)
  • Operating EBITDA was Rs 235 crore in Q3FY24 (YoY growth of 22%) and Rs 729 crore in 9MFY24 (YoY growth of 25%)
    • Operating EBITDA margin was 27.8% in Q3FY24 (YoY improvement of 350 bps) and 27.8% in 9MFY24 (YoY improvement of 330 bps)
  • Gross Margin was 67.6% in Q3FY24 (YoY improvement of 530 bps) and 66.4% in 9MFY24 (YoY improvement of 380 bps)
    • Improvement in gross margins is primarily due to cost optimization and favorable product mix
  • Depreciation increased by 21% to Rs 34 crore in Q3FY24 on account of acquired brands
  • ESOP expenses were Rs 12 crore in Q3FY24 as compared to Rs 7 crore in Q2FY24
  • Other expenses increased by 8% in Q3FY24 to Rs 196 crore due to higher freight costs on account of geo-political issues
  • Net Profit improved by 26% in Q3FY24 and 32% in 9MFY24

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “Our focus on growing the domestic business ahead of the market continues, as reflected in the Q3 performance. The business once again stands out in this quarter. For CY2023, we are the fastest growing company within IPM amongst the top 25 pharma companies. We are excited about our recent Ophthalmology foray which has brought some of the biggest brands in that area into the JB family. The ophthalmology segment holds great promise as we expect this market to grow in mid-teens and consistently outperform IPM growth.

In the international division, the formulations business is stable. Our order book for the CDMO business is looking good for forthcoming quarters. Our approach to developing progressive portfolios is on track, resulting in a positive impact for the exports branded generics business.”

Result PDF

Financial Highlights:

  • For the first quarter ended 30th June 2021, the Company recorded revenue of Rs. 606 crores as compared to Rs. 522.3 crores, registering growth of 16 % over the corresponding quarter ended 30th June, 2020. EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 5 % to Rs. 163.7 crores as compared to Rs. 155.4 crores. EBITDA margin for the quarter was at 27 % as compared to 29.8 %. Profit after Tax was flat at Rs. 118.9 crores as compared to Rs. 119.4 crores.
  • The organization continues to perform well with revenue momentum continuing to remain strong
  • Highest ever quarterly revenue recorded during the first quarter of FY21, despite lockdowns in key markets and supply chain challenges
  • Domestic Formulations business records 39 % growth while the International business revenue was largely flat as compared to Q1 FY21
  • As per MAT June 2021 IQVIA data, Domestic Formulations maintains secular outperformance compared to industry growth rates, driven by strength in chronic segments and expanding prescriber coverage
  • Uncertainty in view of the second wave of COVID-19 impacted growth in certain geographies in the international market during the quarter
  • Gross Margin profile continues to remain healthy at 64 % aided by good product mix
  • EBITDA margin remains strong despite cost base returning to normal level of operations during Q1 FY 22

Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry. Our new GoTo-Market(GTM) model has been implemented and early signs are encouraging, which is reflected in the strong performance of flagship brands and new launches. While demand trends in international business continue to be volatile (given the COVID situation); our key markets like US, S Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival. We expect the performance to improve in select pockets of our international business. Going forward, our priority continues to build on cost efficiency measures while maintaining the same growth momentum”

 

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status